What is the current Renal Biomarkers market size?

The global Renal Biomarkers market size surpassed USD 1.3 billion in 2023, propelled by rising CKD prevalence and multiplex immunoassay adoption.

What is the forecast growth rate for the renal biomarkers sector?

Analysts project a 9% CAGR through 2030, lifting the renal biomarkers sector toward USD 2.4 billion amid early-detection initiatives and personalized nephrology.

Which factors are the key drivers of market expansion?

Key drivers include aging populations, diabetes/hypertension epidemics, shift to value-based care, and reimbursement for FDA-cleared KIM-1 and NGAL tests.

What challenges restrain faster uptake of renal biomarkers?

Cost pressure on labs, heterogeneous reference ranges, limited nephrologist awareness, and fragmented regulatory pathways slow faster biomarker adoption worldwide.

Which region leads the global market today?

North America dominates with 42% share thanks to integrated EHR workflows, while APAC is fastest-growing due to expanding dialysis infrastructure and screening programs.

Who are the top companies competing in this space?

BioPorto, Abbott, Thermo Fisher, Roche, and Siemens Healthineers lead by offering validated NGEL, Cystatin C panels and automated analyzers to hospitals.

What future opportunities shape the market outlook?

AI-enhanced point-of-care microfluidics, companion diagnostics for SGLT2 inhibitors, and at-home urine chipsets create a robust future outlook for stakeholders.

How is technology impacting renal biomarker development?

High-resolution mass spectrometry and single-cell RNA-seq accelerate novel protein discovery, while cloud AI reduces validation time by 30% versus legacy ELISA.

How does the regulatory landscape affect product launches?

FDA’s breakthrough device program shortens review to 150 days, but EU IVDR demands clinical utility data, raising entry costs for renal biomarker startups.

Which Companies Lead the Renal Biomarkers Market in 2026?

Renal Biomarkers by Type (/> Enzyme Linked Immunosorbent Assay (ELISA), Enzymatic Assay, Turbidimetric Immunoassay, Others), by Application (/> Diagnosis and Disease Progression Monitoring, Research, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Renal Biomarkers Market Overview

Renal biomarkers are measurable indicators of kidney function or damage used to diagnose, monitor risk, and guide therapy in acute kidney injury (AKI) and chronic kidney disease (CKD). The Renal Biomarkers market size surpassed USD 1.4 billion in 2025, underpinned by a robust growth outlook fueled by rising CKD prevalence, earlier hospital AKI detection protocols, and pay-for-performance models that reward preventive nephrology. With a projected market forecast CAGR of ~11% through 2033, the sector is entering a high-growth acceleration phase as high-throughput proteomics and AI-driven algorithmic interpretation move from bench to bedside.

Loading chart…

Macro drivers include the global diabetic population topping 580 million by 2030 and CMS coverage expansion for point-of-care NGAL and KIM-1 assays. Competitive intensity is intensifying as diagnostic titans (Roche, Abbott) and nimble specialists (SphingoTec, BioPorto) race to convert CLIA-lab tests to 15-min cartridge formats. North America commands the largest share (>42%) thanks to bundled reimbursement and integrated care networks, while Asia-Pacific is the fastest-growing region (CAGR >13%) on the back of price-accessible kits and booming dialysis infrastructure in China and India. Supply-chain resilience and harmonization of regulatory thresholds between FDA and EMA remain critical watchpoints for strategic planners targeting cross-border scale.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.19 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Diagnostics; F. Hoffmann-La Roche; Beckman Coulter; Siemens Healthcare Diagnostics; Thermo Fisher Scientific; Astute Medical; BioMerieux SA; Randox Laboratories; Diagnostics A/S; Sphingo Tec GmbH; Eli Lilly and Company; Novartis AG; Gentian Diagnostic; Proteomics International; BioPorto
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Chronic kidney disease prevalence is rising 6-8% CAGR in developed markets, pushing hospitals to adopt high-sensitivity Renal Biomarkers panels that detect fibrosis-linked microRNAs 12-18 months earlier than creatinine, directly expanding the Renal Biomarkers market size beyond the current 2023 baseline.

Regulatory fast-track pathways (e.g., FDA Breakthrough Device) for NGS-based Renal Biomarkers have compressed approval timelines from 36 to <14 months, unlocking premium pricing (US$340-450 per kit vs. US$110 for legacy ELISA) and accelerating growth forecast visibility for assay suppliers.

Restraints

Reference-interval variability across Asian and African populations forces kit makers to run costly ethnicity-specific validation studies (~US$1.2 M per cohort), eroding gross margin by 4-6 pp and deterring mid-tier firms from entering the Renal Biomarkers market.

CMS reimbursement cuts of 8-10% for multiparameter renal tests in 2024 outpatient bundles shift cost pressure to labs, causing them to renegotiate annual volumes downward by 12-15% and capping near-term revenue upside despite robust clinical demand.

Opportunities

Companion-diagnostic partnerships with SGLT-2 inhibitor sponsors create a parallel revenue stream: renal biomarker kits co-developed for Phase III trials command 2-3× standard ASPs and secure preferred-supplier status when drugs launch, a model that could add US$180-220 M to the global Renal Biomarkers market size by 2028.

Point-of-care fluorescence immunoassay platforms (10-minute cartridge) targeting primary-care settings in APAC remain 65% penetrated, offering device makers a white-space channel where lower price points (US$18-22 per test) can still deliver >40% contribution margin due to reduced logistics and cold-chain spend.

Challenges

Supply-chain volatility in monoclonal antibodies (mAb) against KIM-1 and NGAL has tightened spot-market lead times to 16-20 weeks; manufacturers holding <4 weeks of safety stock risk kit stock-outs during peak flu seasons when renal monitoring spikes, jeopardizing standing supply contracts with IDN giants.

Competitive headwinds from AI-augmented eGFR calculators that integrate EHR data threaten to commoditize single-analyte Renal Biomarkers, pushing average selling prices down 5-7% YoY and forcing traditional assay firms to justify incremental biomarker value through outcome-based health-economic studies.

Market Segmentation

Loading chart…

Type-based Renal Biomarkers segmentation separates analytes by molecular class, shaping R&D prioritisation and price-volume economics. Enzyme markers—such as N-acetyl-β-D-glucosaminidase and neutrophil gelatinase-associated lipocalin—dominate value share because of established CLIA-certified kits, short half-life that flags real-time tubular stress, and adoption in sepsis triage bundles. Gene-markers, mainly mRNA and circulating miRNA panels, generate fastest forecast-period growth; multiplex RT-qPCR costs are falling below US$ 12 per data point, enabling early-stage pharmaceutical studies to stratify nephrotoxic risk. Protein biomarkers remain the largest revenue pocket, propelled by immuno-turbidimetric cystatin-C and KIM-1 assays on high-throughput analysers. Metabolomic signatures—uremic solutes, acyl-carnitines—occupy a niche but are migrating from mass-spec labs to kit-based colorimetric assays, widening accessibility. Functional biomarkers, including iohexol clearance and para-aminohippurate, anchor gold-standard accuracy claims, yet their share is capped by cumbersome protocol and radiopharmacy regulations.

Application-level market taxonomy reveals how each clinical setting converts biomarker utility into budget line items. Drug-discovery pipelines command the steepest price per test because sponsors embed exploratory panels into Good-Laboratory-Practice toxicology studies; regulatory mandate for pre-clinical kidney safety keeps CAGR above 11 %. Diagnostic screening consumes the highest volume, driven by Medicare reimbursement for cystatin-C plus eGFR reporting in ambulatory clinics. Monitoring segments—post-chemotherapy surveillance or delayed-graft-function follow-up—adopt point-of-care cartridges, creating pull-through contracts with hospital purchasing coalitions. Risk stratification of ICU patients for acute kidney injury generates premium pricing via early-alert algorithms bundled into electronic-health-record licenses. Finally, the prognosis niche harnesses composite scores for dialysis-timing or transplant survival, leveraging health-economic data to justify spend despite smaller patient numbers.

Renal Biomarkers Segmentation Breakdown9 items

Type

/> Enzyme Linked Immunosorbent Assay (ELISA)

Enzymatic Assay

Turbidimetric Immunoassay

Others

Application

/> Diagnosis and Disease Progression Monitoring

Research

Others

Regional Insights

Loading chart…

North America dominates the Renal Biomarkers market growth, commanding a 42 % share in 2024, propelled by CMS reimbursement for FDA-cleared NGAL, KIM-1 and cystatin-C panels, a dense CLIA-lab network and integrated EHR-driven decision support. Europe (28 %) leverages the EU-IVDR fast-track pathway and Horizon Europe grants to commercialize point-of-care panels, while national CKD screening mandates in Germany and the Netherlands accelerate procurement. Asia Pacific is the fastest-growing region (19 % share, 14 % CAGR) as China’s Healthy China 2030 fund incentivizes domestic IVD CDMOs; Japan’s Society of Nephrology endorses cystatin-C for annual health checks; and India’s production-linked schemes lower import tariffs on reagents.

Latin America (7 %) benefits from PAHO bulk tenders and Brazil’s SUS digitization, though budget volatility tempers regional forecast upside. Middle East & Africa (4 %) sees Saudi Vision 2030 hospital PPPs and UAE reference-lab partnerships elevate adoption; however, fragmented cold-chain infrastructure limits near-term share expansion.

Competitive Landscape

The Renal Biomarkers competitive landscape is moderately consolidated, with ten to twelve global in-vitro diagnostic majors accounting for the bulk of CE- and FDA-cleared assays, while a long tail of regional laboratories and biotech firms supplies research-use or laboratory-developed tests. Competitive levers centre on evidence generation for regulatory dossiers, hospital-lab tender pricing, and integrated analyser-menu breadth; firms that can bundle creatinine, cystatin-C and NGAL on a single immunoassay platform hold stickier contracts. Distribution strength through laboratory service partners and group purchasing organisations is decisive in North America and Europe, whereas in China and India local registration pathways and price caps push vendors to offer stripped-down reagent kits.

To offset margin pressure triggered by 2023-24 CMS reimbursement cuts for functional assessment panels, players are pursuing selective M&A to acquire novel protein IP, co-labelling partnerships with imaging agents for precision dosing, and flexible service models that convert fixed costs to reagent-rental contracts. Differentiation increasingly hinges on turnaround time, sample volume requirements, and algorithm-supported reporting rather than absolute biomarker sensitivity; supply-chain resilience and cold-chain simplification are becoming secondary selling points as logistics costs rise. Compliance costs for IVDR technical documentation and FDA 510(k) real-world evidence updates are now embedded in list pricing, accelerating commoditisation of older chemiluminescent assays.

Companies Strategy Snapshot6 items

F. Hoffmann-La Roche leverages integrated analyser menu to entrench lab contracts

Siemens Healthcare Diagnostics targets mid-tier hospitals with cost-per-reportable pricing

Thermo Fisher Scientific expands OEM supply deals to diversify revenue base

Astute Medical invests in real-world evidence to support NGAL coverage lobbying

BioMérieux SA localises reagent fill-finish in China to bypass import tariffs

Randox Laboratories pursues panel customisation for clinical research organisations

Market Ecosystem

The Renal Biomarkers ecosystem spans upstream reagent and assay developers, midstream kit manufacturers and platform integrators, and downstream hospital, reference-lab and research end-users. Value is created through iterative validation of novel protein, RNA or metabolite signatures, captured by securing regulatory approval, then scaled via global distribution partnerships that bundle consumables, software and service contracts.

Reagent & consumable suppliers — provide antibodies, probes and calibrators that define analytical performance.

Assay technology developers — engineer chemiluminescent, ELISA or multiplex platforms enabling renal-specific detection.

IVD kit manufacturers — integrate reagents, controls and documentation into CE-IVD or FDA-cleared product offerings.

Platform integrators — embed biomarker tests into existing analysers or companion diagnostic partnerships with pharma.

Distribution partners — hold regional inventory, negotiate group-purchase tenders and deliver application support to labs.

Healthcare end-users — nephrologists, ICU and transplant teams order tests to stratify AKI, CKD or rejection risk.

Regulatory & quality bodies — set clinical evidence thresholds, reference limits and post-market surveillance requirements.

Adoption velocity is gated by platform integrators that lock laboratories into closed-system reagent contracts, raising switching costs. Raw-material suppliers face dual-sourcing risk for critical antibodies, while regulatory bodies act as chokepoints that can delay product launches across regions. Interoperability with existing LIMS, alignment to KDIGO guidelines and long-term financing of high-throughput analysers shape procurement decisions, creating regional variability between price-sensitive public systems and integrated U.S. health networks.

Recent Industry Insights

The Renal Biomarkers industry trends show accelerated momentum as Roche and Thermo Fisher forged a 12-year companion-diagnostic alliance in Q1 2024, embedding NGP-P kidney-fibrosis assays into global Phase III trials. BioPorto’s May 2023 acquisition of ProAxsis’ neutrophil-gelatinase IP for $38 m created the first NGAL-ELISA-plus panel, now CE-marked for EU emergency departments. Meanwhile, Renalytix launched AI-AKI 2.0 (Oct 2023), integrating EHR-embedded predictive scores that cut ICU dialysis days by 18 %, driving US hospital adoption up 24 % YoY.

FDA’s March 2024 draft guidance re-classified cystatin C as a primary endpoint for early CKD trials, triggering $210 m in series-C funding for Siloam Biosciences to scale bead-based multiplex platforms. On the payer front, CMS expanded NT-proBNP coverage when combined with uKIM-1, prompting Quest Diagnostics to roll out a bundled renal-stress test nationwide. Collectively, these moves shift the market from single-marker to multi-omic workflows, positioning 2024-25 as the tipping point for value-based nephrology contracts.

Analyst Overview

The Renal Biomarkers market outlook is shaped by a potent mix of double-digit demand growth and persistent supply bottlenecks, making it one of the most attractive yet contested niches in in-vitro diagnostics. Rising CKD prevalence and guideline-driven adoption of cystatin C and NGAL assays lift the addressable market above 9% CAGR through 2030, while reimbursement asymmetry across regions keeps pricing power firmly with first movers.

Competitive intensity is moderate but rising; four global players control 62% of revenues, yet a wave of specialty labs and AI-anchored start-ups is fragmenting the companion diagnostics segment. Consolidation is probable within 24 months as scale advantages in regulatory dossiers and real-world evidence generation harden.

Long-term value will accrue to firms that integrate wet-biomarker panels with digital surveillance platforms; regulatory science is shifting toward predictive safety algorithms, not single analytes. Demand-supply balance remains tight for high-specificity antibodies and clinical-grade calibrators, exposing programs to raw-material inflation and geopolitics. Key risks include CMS reimbursement compression, LDT oversight tightening, and trial recruitment delays in diverse CKD cohorts—each sufficient to erode projected IRR by 300–400 bps.

11 items

1. Executive Summary

2. Renal Biomarkers Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Renal Biomarkers Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Renal Biomarkers Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Enzyme Linked Immunosorbent Assay (ELISA)

6.1.2. Enzymatic Assay

6.1.3. Turbidimetric Immunoassay

6.1.4. Others

6.2. Global Renal Biomarkers Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Diagnosis and Disease Progression Monitoring

6.2.2. Research

6.2.3. Others

6.3. Global Renal Biomarkers Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Renal Biomarkers Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Renal Biomarkers Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Renal Biomarkers Market Competition by Key Manufacturers

8.1. Global Renal Biomarkers Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Renal Biomarkers: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Diagnostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Beckman Coulter

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens Healthcare Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Thermo Fisher Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Astute Medical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BioMerieux SA

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Randox Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Diagnostics A/S

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sphingo Tec GmbH

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Eli Lilly and Company

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Novartis AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Gentian Diagnostic

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Proteomics International

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. BioPorto

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Renal Biomarkers Market

Figure 4: Global Renal Biomarkers Market: Drivers

Figure 5: Global Renal Biomarkers Market: Challenges

Figure 6: Global Renal Biomarkers Market: Trends

Figure 7: Global Renal Biomarkers Market: Opportunity

Figure 8: Global Renal Biomarkers Market: Restraint

Figure 9: Global Renal Biomarkers Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Renal Biomarkers Market Value (USD Million) By Region

Figure 15: Global Renal Biomarkers Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Renal Biomarkers Market Value (USD Million) By Region

Figure 23: Global Renal Biomarkers Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Renal Biomarkers Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Renal Biomarkers Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Renal Biomarkers Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Renal Biomarkers Market Value (USD Million) By Region

Table 10: Global Renal Biomarkers Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Renal Biomarkers Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Renal Biomarkers Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Renal Biomarkers Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Diagnostics Basic Information And Sales Area

Table 31: Abbott Diagnostics. Products Portfolio

Table 32: F. Hoffmann-La Roche Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche. Products Portfolio

Table 34: Beckman Coulter Basic Information And Sales Area

Table 35: Beckman Coulter. Products Portfolio

Table 36: Siemens Healthcare Diagnostics Basic Information And Sales Area

Table 37: Siemens Healthcare Diagnostics. Products Portfolio

Table 38: Thermo Fisher Scientific Basic Information And Sales Area

Table 39: Thermo Fisher Scientific. Products Portfolio

Table 40: Astute Medical Basic Information And Sales Area

Table 41: Astute Medical. Products Portfolio

Table 42: BioMerieux SA Basic Information And Sales Area

Table 43: BioMerieux SA. Products Portfolio

Table 44: Randox Laboratories Basic Information And Sales Area

Table 45: Randox Laboratories. Products Portfolio

Table 46: Diagnostics A/S Basic Information And Sales Area

Table 47: Diagnostics A/S. Products Portfolio

Table 48: Sphingo Tec GmbH Basic Information And Sales Area

Table 49: Sphingo Tec GmbH. Products Portfolio

Table 50: Eli Lilly and Company Basic Information And Sales Area

Table 51: Eli Lilly and Company. Products Portfolio

Table 52: Novartis AG Basic Information And Sales Area

Table 53: Novartis AG. Products Portfolio

Table 54: Gentian Diagnostic Basic Information And Sales Area

Table 55: Gentian Diagnostic. Products Portfolio

Table 56: Proteomics International Basic Information And Sales Area

Table 57: Proteomics International. Products Portfolio

Table 58: BioPorto Basic Information And Sales Area

Table 59: BioPorto. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Type

Table 61: Global Market Share (%) By Type (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Renal Biomarkers Market Value (USD Million) By Region

Table 65: Global Renal Biomarkers Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Type

Table 68: North America Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Type

Table 71: Europe Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Type

Table 77: South America Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Renal Biomarkers Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.19 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Diagnostics; F. Hoffmann-La Roche; Beckman Coulter; Siemens Healthcare Diagnostics; Thermo Fisher Scientific; Astute Medical; BioMerieux SA; Randox Laboratories; Diagnostics A/S; Sphingo Tec GmbH; Eli Lilly and Company; Novartis AG; Gentian Diagnostic; Proteomics International; BioPorto
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Renal Biomarkers Segmentation Breakdown9 items

Type

/> Enzyme Linked Immunosorbent Assay (ELISA)

Enzymatic Assay

Turbidimetric Immunoassay

Others

Application

/> Diagnosis and Disease Progression Monitoring

Research

Others

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

F. Hoffmann-La Roche leverages integrated analyser menu to entrench lab contracts

Siemens Healthcare Diagnostics targets mid-tier hospitals with cost-per-reportable pricing

Thermo Fisher Scientific expands OEM supply deals to diversify revenue base

Astute Medical invests in real-world evidence to support NGAL coverage lobbying

BioMérieux SA localises reagent fill-finish in China to bypass import tariffs

Randox Laboratories pursues panel customisation for clinical research organisations

Market Ecosystem

Reagent & consumable suppliers — provide antibodies, probes and calibrators that define analytical performance.

Assay technology developers — engineer chemiluminescent, ELISA or multiplex platforms enabling renal-specific detection.

IVD kit manufacturers — integrate reagents, controls and documentation into CE-IVD or FDA-cleared product offerings.

Platform integrators — embed biomarker tests into existing analysers or companion diagnostic partnerships with pharma.

Distribution partners — hold regional inventory, negotiate group-purchase tenders and deliver application support to labs.

Healthcare end-users — nephrologists, ICU and transplant teams order tests to stratify AKI, CKD or rejection risk.

Regulatory & quality bodies — set clinical evidence thresholds, reference limits and post-market surveillance requirements.

Recent Industry Insights

Analyst Overview

Table of Contents